Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MABp1 · 2 trials · 2 indications
Pharmacokinetics--blood levels of MABp1 antibody
Pharmacokinetics--blood levels of MABp1 antibody
Pharmacokinetics--blood levels of MABp1 antibody
Pharmacokinetics--blood levels of MABp1 antibody
| Arm | Type | Description |
|---|---|---|
| MABp1 | EXPERIMENTAL | - |
| MTD | EXPERIMENTAL | The study will utilize a standard 3+3 design for dose escalation. Once the maximum tolerated dose has been reached, an expansion cohort, as well as tumor specific expansion cohorts will be explored. |
| Name | Type | Description |
|---|---|---|
| MABp1 | BIOLOGICAL | Single dose of intravenous MABp1 |
Inclusion Criteria: 1. Age: ≥18 2. Adequate bone marrow function as defined as: * absolute neutrophil count (neutrophil and bands) of ≥ 1,500/mm3 (≥ 1.5 x 109/L) * platelet count \> 150,000/mm3 * hemoglobin of ≥ 10 g/dL 3. Adequate renal function, defined by serum creatinine ≤ 1.5 x lab U...
MABp1 is an investigational drug being studied for use in advanced cancers and in healthy volunteers. It is in Phase 1 clinical development for oncology indications. The drug is not approved and remains under investigation.
MABp1 is being developed by Johnson & Johnson, a company traded on the New York Stock Exchange under the ticker JNJ. The drug is in Phase 1 clinical development.
MABp1 is in Phase 1 clinical development. It has completed two Phase 1 trials, one in patients with advanced cancers and one in healthy volunteers. The drug is investigational and not yet approved.
MABp1 has been studied in two completed Phase 1 trials. NCT01021072 enrolled 52 patients with advanced cancers in the United States. NCT03047317 enrolled 6 healthy volunteers in the United States. Both trials are completed.
No alternative names for MABp1 have been disclosed. The drug is known only by the name MABp1 in its clinical development program.